High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: A study of ocular benefits

Eye

Volumn 19, Issue 8, 2005, Pages 846-853

  Yip, Leonard W ^a   Thong, B Y ^a   Tan, A W ^b   Khin, L W ^c   Chng, H H ^a   Heng, W J ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL SKIN CENTRE   (Singapore)

^c MINISTRY OF HEALTH   (Singapore)

Author keywords

Intravenous immunoglobulins; Ocular complications; Toxic epidermal necrolysis

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTIBIOTIC AGENT; COTRIMOXAZOLE; FUROSEMIDE; IMMUNOGLOBULIN; LUBRICATING AGENT; OMEPRAZOLE; PHENYLBUTAZONE; PHENYTOIN; PROCHLORPERAZINE; RIFAMPICIN; STEROID; SULTAMICILLIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG UTILIZATION; EYE DISEASE; FEMALE; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICAL RECORD; MEDICAL SPECIALIST; RASH; RETROSPECTIVE STUDY; SEPTIC SHOCK; SINGAPORE; SURVIVAL; SYMBLEPHARON; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

EID: 23944452902     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701653     Document Type: Article

References (25)

1. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-1165.
2. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-842.
3. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102: 1669-1676.
4. Pichler W, Yawalkar N, Schmid S, Helbling A. Pathogenesis of drug-induced exanthems. Allergy 2002; 57: 884-893.
5. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
6. Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203: 45-49.
7. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
8. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-552.
9. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-36.
10. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol 1973; 90: 376-379.
11. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
12. Lyell A. A review of toxic epidermal necrolysis in Britain. Br J Dermatol 1967; 79: 662-671.
13. Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984; 120: 721-726.
14. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13: 623-635.
15. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-512.
16. Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881-887.
17. Kelemen III JJ, Cioffi WG, McManus WF, Mason Jr AD, Pruitt Jr BA. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 273-278.
18. Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 1999; 40: 131-134.
19. Roujeau JC, Phlippoteau C, Koso M, Wechsler J, Andre C, Binaghi M et al. Sjogren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet 1985; 1: 609-611.
20. Revuz J, Roujeau JC, Guillaume JC, Penso D, Touraine R. Treatment of toxic epidermal necrolysis. Creteil's experience. Arch Dermatol 1987; 123: 1156-1158.
21. Bachot N, Roujeau JC. Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr Opin Allg Clin Immunol 2003; 3: 269-274.
22. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48: 473-478.
23. Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol 1998; 139: 1127-1128.
24. Bamichas G, Natse T, Christidou F, Stangou M, Karagianni A, Koukourikos S et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002; 6: 225-228.
25. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589.